Breast Cancer

Overview

The breast cancer evidence focuses on its capacity for apoptosis, PI3K/Akt and MAPK inhibition, angiogenesis suppression, and SOC-treatment-synergy logic. Subtype matters here more than in almost any other cancer area — the ER+, TNBC, and HER2+ pictures are meaningfully different, and the resveratrol overlap adds an extra interpretive layer across all three.

Key findings

• Downregulates CREB phosphorylation and induces apoptosis in MDA-MB-231 and MCF-7 cells

• Inhibits PI3K/Akt and MAPK pathways in breast cancer models

• Suppresses VEGF and broader angiogenic signalling

• Shows synergy with sorafenib and with glucose-metabolism-targeting strategies in preclinical work

TNBC

Triple-negative breast cancer is the subtype where polydatin's direct preclinical signal is strongest and most mechanistically specific. In MDA-MB-231 and SUM159 TNBC cell lines, polydatin combined with the Nrf2 inhibitor brusatol significantly inhibited cell proliferation by downregulating the Nrf2/HO-1/NQO1 pathway and driving ROS accumulation — and crucially, the combination achieved this at one-third the dose of either agent alone, reducing toxicity concerns while preserving efficacy in animal models.

Separately, polydatin alone induced G2/M cell cycle arrest, apoptosis, and autophagy via ROS/JNK signalling in MDA-MB-231 and MDA-MB-468 TNBC cells.

Because polydatin is metabolised toward resveratrol, the broader resveratrol–TNBC literature is directly relevant context. Resveratrol promotes apoptosis in MDA-MB-231 cells through a POLD1-dependent pathway — suppressing POLD1 expression activates caspase-3 cleavage and reduces tumour growth in nude mouse models — and this effect was concentration- and time-dependent, with 50 µM at 36 hours identified as an optimal treatment window.

Resveratrol also shows synergy with FL118, leading to G1-phase accumulation and suppression of survival gene expression in TNBC cells. The TNBC landscape is one where the polydatin-to-resveratrol metabolic arc appears to work with, rather than against, the desired anticancer direction.

ER+ breast cancer

The ER+ picture requires greater nuance because resveratrol's behaviour in oestrogen receptor-positive cells is demonstrably biphasic. At low concentrations (around 5 µM), resveratrol stimulated MCF-7 cell proliferation by approximately 21%, while higher concentrations (above 10 µM) shifted to inhibition — a pattern not observed in ER-negative MDA-MB-231 cells.

The proposed mechanism involves resveratrol inhibiting the sulphation of estrogen metabolites in MCF-7 cells, thereby paradoxically elevating free estradiol (E2) levels and driving receptor-mediated proliferation at lower doses.

This dose-dependency matters when interpreting polydatin studies in MCF-7 cells, since the reported apoptosis-inducing effects occur at concentrations well above the proliferation-stimulating threshold.

At higher concentrations, the picture improves: resveratrol activates p53 in MCF-7 and T-47D ER+ cells, contributing to anti-proliferative effects, and modulates NF-Y/p53/Sin3/HDAC1 complexes relevant to tamoxifen-resistant ER+ disease.

Polydatin's specific research in MCF-7 involves CREB pathway suppression and induction of apoptosis, which are mechanistically distinct from the resveratrol estrogen-metabolism concern — but the metabolic conversion link means that, in ER+ contexts, dose level and clinical setting warrant careful consideration.

This is a "watch this space" area rather than a blanket contraindication, but it warrants explicit acknowledgement in any discussion of ER+ subtypes.

HER2-specific caution

Because polydatin is metabolised toward resveratrol, HER2-positive breast cancer deserves extra caution and clinician review.

The most important concern here is not HER2 positivity per se. It is the unresolved Δ16HER2-related resveratrol signal reported in a HER2-positive / ER-positive breast cancer model. That means this is best framed as a HER2-positive/ER-positive breast-cancer caution, not a blanket statement about every HER2-positive cancer.

For a fuller explanation, see the Polydatin-specific page on HER2+ Cancers.

Practical interpretation

Breast cancer is one of the richest mechanistic areas for polydatin, but also one where subtype-specific interpretation matters most. The TNBC signal — particularly via Nrf2/ROS pathways and the brusatol combination — is the most directly supported by polydatin-specific data. The ER+ picture carries a resveratrol-related nuance around dose and oestrogen metabolism that warrants caution with ER+ group members.

References

Polydatin down-regulates the phosphorylation level of CREB and induces apoptosis in human breast cancer cells
https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0176501

Polydatin synergises with 2-deoxyglucose to inhibit PI3K/AKT/HIF-1α/HK2 signalling axis in breast cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC6484306/

Natural Compounds, Optimal Combination of Brusatol and Polydatin Promote Anti-Tumour Effect in Breast Cancer by Targeting Nrf2 Signalling Pathway
https://pmc.ncbi.nlm.nih.gov/articles/PMC10179160/

Anti-proliferation of triple-negative breast cancer cells with polydatin via ROS/JNK signalling
https://www.oncotarget.com/article/19299/text/

Resveratrol mediates the apoptosis of triple-negative breast cancer cells by reducing POLD1 expression
https://pmc.ncbi.nlm.nih.gov/articles/PMC7970754/

Resveratrol inhibits key steps of steroid metabolism in ERα+ MCF-7 breast cancer cells
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00742/full

Resveratrol fuels HER2-positive breast cancer behaving as an oncogenic compound in Δ16HER2 transgenic mice
https://pmc.ncbi.nlm.nih.gov/articles/PMC5361678/